The ECF-A tetrapeptides and histamine selectively enhance human eosinophil complement receptors.
D001665:Binding Sites / Q000187:drug effects*; D002462:Cell Membrane / Q000187:drug effects; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D003165:Complement System Proteins / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004804:Eosinophils / Q000187:drug effects / Q000502:physiology*; D006632:Histamine / Q000494:pharmacology*; D006801:Humans; D007074:Immunoglobulin G; D009000:Monocytes / Q000187:drug effects; D009504:Neutrophils / Q000378:metabolism; D009842:Oligopeptides / Q000494:pharmacology*; D012397:Rosette Formation
D007074:Immunoglobulin G; D009842:Oligopeptides; D006632:Histamine; D003165:Complement System Proteins